Meeting
2018 ASCO Annual Meeting
A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.
Authors
Dongmei Ji
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Dongmei Ji , Weina Shen , Hongzhen Li , Yan Xia , Yu Wang , Shiping Luo , Qunmin Zhou , Yiqing Xu , Junning Cao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Antibodies
Clinical Trial Registration Number
CTR20160585
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2522)
DOI
10.1200/JCO.2018.36.15_suppl.2522
Abstract #
2522
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward
Poster
2017 ASCO Annual Meeting
A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.
First Author: Nai-Jung Chiang
Poster
2017 ASCO Annual Meeting
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.
First Author: Shiraj Sen
Poster
2013 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
First Author: Lee S. Rosen